National Kidney Foundation, American Society for Clinical Pathology, Leading Laboratories and Clinical Laboratory Societies Unite to Diagnose Chronic Kidney Disease

New “Kidney Profile” Simplifies Diagnostic Tests with Aim to Help Detect Disease Early

QUOTE SHEET

“With diabetes and high blood pressure the leading causes of chronic kidney disease (CKD)—and many unaware that they even have it—laboratory screening is absolutely vital for identifying and monitoring the disease early. ARUP Laboratories is pleased to align with the National Kidney Foundation and other laboratories to detect and improve care for CKD patients,” said Sherrie Perkins, MD, CEO ARUP Laboratories.

“One in three American adults are at risk for chronic kidney disease, and screening within the primary care setting is crucial in identifying patients with early stage renal disease,” said James Weisberger, M.D. Executive Vice President, Chief Medical Officer, Laboratory Director at BioReference Laboratories, an OPKO Health Company. “Aligning with the National Kidney Foundation, the American Society for Clinical Pathology, and other national laboratories to standardize testing will enable physicians to more easily identify and diagnose patients at risk, and begin monitoring and appropriate therapy before disease progresses. We are pleased to be part of this initiative.”

“Testing performed within our clinical laboratories plays a key role in the prevention, diagnosis, treatment and monitoring of disease. The Clinical Laboratory Management Association is pleased to work with the National Kidney Foundation to engage our members in detecting, treating and improving overall care for Chronic Kidney Disease patients,” said Jane M. Hermansen MBA, MT(ASCP), CLMA President.

“LabCorp is pleased to be part of this effort to improve care for patients with chronic kidney disease (CKD),” said Jennifer Ennis, Medical Director, Litholink, a member of the LabCorp Specialty Testing Group and Clinical Assistant Professor of Medicine, Nephrology, University of Illinois at Chicago. “For many years, Litholink has focused on improving CKD diagnosis and treatment, and we fully support this effort to implement a standardized lab panel focused specifically on CKD, to both simplify the detection process for primary care physicians and help them better identify those patients at greatest risk for disease progression and related complications, including cardiovascular disease and other co-morbidities.”

“With the convenience of ordering the new CKD “Kidney Profile”, patients can be diagnosed earlier with chronic kidney disease (CKD). Earlier diagnosis of CKD can decrease the morbidity associated with CKD by earlier intervention. This important collaboration with the implementation of the new Kidney Profile will have a positive impact on patient outcomes,” said M. Fred Bugg, M.D., NILA/AAB.

“Quest Diagnostics recognizes the importance of diagnosing chronic kidney disease as early as possible in order to help slow the progression of the disease, which may result in kidney failure,” said Lee Hilborne, MD, MPH, Medical Director, Quest Diagnostics. “That’s why Quest is committed to collaborating with organizations like the National Kidney Foundation that champion tools such as the new ‘Kidney Profile,’ which make it easier for doctors in a primary care setting to diagnose their patients.”
“Sonic Healthcare USA is pleased to be a part of this important initiative in the diagnosis of chronic kidney disease. Working to standardize laboratory testing to identify patients with chronic kidney disease earlier, complements our existing patient engagement program for routine monitoring and follow up for these patients. Furthermore, this initiative mirrors Sonic Healthcare’s commitment to high quality laboratory testing and improving patient care,” said Jerry W. Hussong, MD, Sonic Healthcare USA’s Chief Medical Officer.